An observational study in Left Ventricular Hypertrabeculation and Left Ventricular Noncompaction, sponsored by First Affiliated Hospital Xi'an Jiaotong University. Recruiting at 1 site in China. Per ClinicalTrials.gov, last updated 2026-11-18.
Sponsored by First Affiliated Hospital Xi'an Jiaotong University · Observational
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
The goal of this observational study is to describe the clinical phenotypes, natural history, and long-term outcomes of left ventricular hypertrabeculation/noncompaction (LVHT/LVNC) in patients of all ages. LVHT/LVNC is a heart muscle characteristic identified by cardiac imaging that may occur alone or in association with cardiomyopathies or other heart diseases.
The main questions this study aims to answer are:
Researchers will compare patients with isolated LVHT/LVNC, those with associated cardiomyopathies, and those with other cardiac diseases or specific clinical conditions to better understand differences in disease progression and long-term outcomes.
Participants will:
The study will not change participants' usual medical care or require additional invasive procedures for research purposes.
Background and Rationale
Left ventricular hypertrabeculation/noncompaction (LVHT/LVNC) is a cardiac morphological phenotype characterized by prominent ventricular trabeculations and deep intertrabecular recesses. Traditionally considered a distinct cardiomyopathy, LVNC is increasingly recognized as a heterogeneous morphological feature that may occur in isolation or in association with cardiomyopathies, other cardiovascular diseases, and specific physiological or clinical conditions.
The clinical significance of LVHT/LVNC remains uncertain. Although some patients develop heart failure, ventricular arrhythmias, thromboembolic events, or other adverse cardiovascular outcomes, others remain asymptomatic with preserved cardiac function. Differences in imaging diagnostic criteria, underlying cardiac diseases, ventricular function, and myocardial fibrosis may contribute to the substantial heterogeneity observed across patient populations.
Longitudinal evidence regarding the natural history, clinical phenotype transitions, and long-term outcomes of LVHT/LVNC remains limited, particularly in large, multicenter populations encompassing different age groups and clinical backgrounds.
Study Objectives
The CAPTAIN study aims to establish a nationwide multicenter registry to characterize the clinical phenotypes, natural history, and long-term outcomes of patients with LVHT/LVNC.
The specific objectives are to describe the clinical spectrum of LVHT/LVNC; evaluate longitudinal changes in cardiac structure, ventricular function, and clinical phenotypes; assess associations between clinical phenotypes and long-term cardiovascular outcomes; and establish a linked clinical and biological specimen resource for future research.
Study Design and Population
CAPTAIN is a nationwide, multicenter, observational registry cohort study combining retrospective and prospective enrollment.
The retrospective cohort includes eligible patients identified from January 1, 2018, through the date of ethics approval of the amended protocol. Prospective enrollment will continue through December 31, 2045, with core follow-up planned for up to 5 years per participant and final follow-up expected by December 31, 2050.
Patients of all ages with an LVHT/LVNC phenotype confirmed by echocardiography, cardiovascular magnetic resonance (CMR), or other applicable cardiac imaging modalities are eligible.
The study includes patients with isolated LVHT/LVNC, those with associated cardiomyopathies, and those with other cardiac diseases or specific clinical conditions. The presence of concomitant cardiovascular diseases does not automatically exclude participation.
Imaging findings will be evaluated using prespecified criteria and standardized review procedures. Clinical phenotypes will be classified according to underlying cardiac diseases, ventricular structure and function, and relevant clinical characteristics. Overlapping clinical features will be recorded when applicable.
Data Collection and Follow-up
Baseline data will include demographic characteristics, medical and family history, clinical diagnoses, comorbidities, electrocardiographic findings, echocardiographic and CMR measurements, available laboratory and genetic testing results, and treatments received during routine clinical care.
Prospective follow-up is planned at 6 months, 12 months, and annually from years 2 through 5. Follow-up information will be obtained through routine clinical visits, medical records, or telephone contact, as appropriate.
Longitudinal assessments will focus on changes in ventricular structure and function, myocardial trabeculation characteristics, clinical phenotypes, treatments, and cardiovascular outcomes. No additional cardiac imaging examinations are mandated solely for research purposes.
Study Outcomes
The primary outcome is the time to the first occurrence of a composite endpoint comprising all-cause death, hospitalization for new or worsening heart failure, serious ventricular arrhythmias, initiation of long-term mechanical circulatory support, or heart transplantation within 5 years from baseline.
Secondary outcomes include individual components of the primary composite endpoint, cardiovascular death, sudden cardiac death, recurrent heart failure hospitalizations, new-onset atrial fibrillation, ischemic stroke, systemic thromboembolism, and left ventricular thrombus.
Additional assessments include longitudinal changes in ventricular dimensions, ventricular volumes, left ventricular ejection fraction, myocardial fibrosis, trabeculation characteristics, and clinical phenotype transitions.
Biological Specimen Collection and Exploratory Research
An optional nested biospecimen cohort will be established among participants providing appropriate consent.
Research blood and other approved body fluid samples may be collected during clinically indicated sampling procedures. Tissue specimens may be obtained only from residual materials remaining after clinically indicated diagnostic or therapeutic procedures.
The availability of biological specimens is not required for enrollment or continued follow-up.
Linked clinical and biological resources may support future imaging, genetic, pathological, and molecular investigations, subject to applicable consent, ethics approval, and resource governance requirements.
Observational Nature of the Study
CAPTAIN is a non-interventional study. Diagnostic evaluations, medical treatment, device therapy, and surgical procedures will be determined by treating physicians according to routine clinical practice.
No treatment will be assigned by the study, and no additional invasive procedures will be performed solely for research purposes.
First Affiliated Hospital Xi'an Jiaotong University is the lead sponsor of 318 studies on the registry; 91 are open to participants now.
Counted across the registry records on this site, refreshed daily.
The criteria were revised on the registry on Nov 18, 2026. See what changed
The study population includes patients of all ages with imaging-confirmed left ventricular hypertrabeculation/noncompaction (LVHT/LVNC) identified at participating medical centers in China. Eligible participants include individuals with isolated LVHT/LVNC, associated cardiomyopathies, other cardiac diseases, or specific clinical conditions. Retrospective participants will be identified from existing clinical records dated January 1, 2018, through the date of ethics approval of the amended protocol. Prospective participants will be consecutively enrolled after approval of the amended protocol through December 31, 2045. Eligibility does not require CMR, genetic testing, or biospecimen availability.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Additional Eligibility Considerations:
Patients with isolated LVHT/LVNC, associated cardiomyopathies, congenital heart disease, ischemic heart disease, valvular heart disease, or other relevant cardiac or systemic conditions may be included.
CMR, genetic testing, and biospecimen collection are not mandatory for enrollment. The absence of available biospecimens does not constitute an exclusion criterion.
Patients with borderline or uncertain imaging findings will undergo further review and will not be included in the primary study population until the LVHT/LVNC phenotype has been adequately confirmed.
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Patients of all ages with imaging-confirmed left ventricular hypertrabeculation/noncompaction (LVHT/LVNC), identified from existing clinical records between January 1, 2018, and the date of ethics approval of the amended protocol. Retrospectively available demographic, clinical, imaging, laboratory, treatment, and follow-up data will be collected. Patients may have isolated LVHT/LVNC, associated cardiomyopathies, or other cardiac diseases and clinical conditions. Existing outcomes will be assessed using standardized definitions. No study-assigned interventions or additional clinical procedures will be performed.
Patients of all ages with imaging-confirmed LVHT/LVNC, prospectively enrolled following ethics approval of the amended protocol through December 31, 2045. Participants may have isolated LVHT/LVNC, associated cardiomyopathies, or other cardiac diseases and clinical conditions. Baseline clinical and imaging information will be recorded, with follow-up planned at 6 months, 12 months, and annually from years 2 through 5. Clinical outcomes and longitudinal changes in cardiac structure and function will be assessed. Optional biospecimens may be collected during routine clinical care with appropriate consent. No study-assigned treatments or additional invasive procedures are required.
Time to First Major Adverse Clinical Event (Composite Outcome)
Time from baseline to the first occurrence of any of the following events: all-cause death; hospitalization for new or worsening heart failure; serious ventricular arrhythmia (sustained ventricular tachycardia, ventricular fibrillation, resuscitated cardiac arrest, or appropriate implantable cardioverter-defibrillator therapy); first initiation of long-term mechanical circulatory support; or first heart transplantation. Events occurring before baseline will be recorded as medical history and will not count as incident events. Pre-existing heart failure during the index hospitalization will not count as a new heart failure hospitalization event. The first qualifying event will be used for the composite endpoint.
Time frame: From baseline through 5 years
Number of Participants with All-Cause Mortality
Death from any cause during follow-up. The date of death will be determined from available medical records, follow-up contacts, or other permitted sources. Deaths occurring before baseline will not be counted as incident events.
Time frame: From baseline through 5 years
Number of Participants with Cardiovascular Mortality
Death attributable to cardiovascular causes, including heart failure, sudden cardiac death, myocardial infarction, stroke, or other cardiovascular conditions. Causes of death will be determined from available clinical documentation and adjudicated using standardized definitions.
Time frame: From baseline through 5 years
Number of Participants Hospitalized for New or Worsening Heart Failure
First hospitalization after baseline for new-onset or worsening heart failure requiring inpatient clinical management. Events will be verified using available hospitalization records. Heart failure already present during the index hospitalization will not be counted as a new hospitalization event.
Time frame: From baseline through 5 years
Number of Participants Experiencing Serious Ventricular Arrhythmias
First occurrence after baseline of sustained ventricular tachycardia, ventricular fibrillation, resuscitated cardiac arrest, or appropriate implantable cardioverter-defibrillator therapy. Events will be verified using electrocardiographic recordings, device interrogation reports, hospitalization records, or other available clinical documentation.
Time frame: From baseline through 5 years
Number of Participants Initiating Long-Term Mechanical Circulatory Support
Number of participants who undergo first implantation or initiation of durable mechanical circulatory support after baseline for advanced heart failure, including durable ventricular assist devices or other long-term mechanical circulatory support systems. Temporary mechanical circulatory support used for acute stabilization will not be counted. Events will be verified using available clinical or surgical records.
Time frame: From baseline through 5 years
Number of Participants Undergoing Heart Transplantation
First heart transplantation performed after baseline, as confirmed by transplant records or other available clinical documentation. The transplantation date will be recorded for time-to-event analyses.
Time frame: From baseline through 5 years
Number of Participants with New-Onset Atrial Fibrillation
Number of participants without a documented history of atrial fibrillation at baseline who develop new-onset atrial fibrillation during follow-up. Atrial fibrillation must be clinically documented by electrocardiography, ambulatory electrocardiographic monitoring, device interrogation, or other appropriate clinical records. The number and proportion of participants with newly documented atrial fibrillation will be reported.
Time frame: From baseline through 5 years
Number of Participants with Ischemic Stroke or Systemic Thromboembolism
Number of participants experiencing at least one clinically confirmed ischemic stroke or systemic arterial thromboembolic event after baseline during follow-up. Events will be identified and verified using available medical records, diagnostic imaging, and relevant clinical documentation. Ischemic stroke and systemic arterial thromboembolism will also be recorded and reported separately.
Time frame: From baseline through 5 years
Number of Participants with Newly Detected Left Ventricular Thrombus
Number of participants without documented left ventricular thrombus at baseline who develop newly detected left ventricular thrombus during follow-up. Left ventricular thrombus will be identified by clinically performed echocardiography, cardiovascular magnetic resonance, or other appropriate cardiac imaging. The number and proportion of participants with newly detected left ventricular thrombus will be reported.
Time frame: From baseline through 5 years
Number of Recurrent Heart Failure Hospitalizations
Total number of hospitalizations for new or worsening heart failure occurring after baseline, including recurrent hospitalizations in the same participant. Events will be identified from available clinical records and evaluated using appropriate recurrent-event methods.
Time frame: From baseline through 5 years
Change in Left Ventricular Ejection Fraction
Change in left ventricular ejection fraction (LVEF), measured in percentage points, from baseline to available follow-up assessments using clinically performed echocardiography or cardiovascular magnetic resonance. Longitudinal changes will be assessed using available repeated measurements, with imaging modalities evaluated separately when appropriate.
Time frame: Baseline and up to 5 years
Change in Noncompacted-to-Compacted Myocardial Thickness Ratio
Change in the noncompacted-to-compacted myocardial thickness ratio (NC/C ratio) from baseline to follow-up, assessed using clinically performed echocardiography or cardiovascular magnetic resonance (CMR). The NC/C ratio will be measured using prespecified, modality-specific imaging methods. Changes in the ratio will be evaluated using available repeated imaging measurements. Echocardiographic and CMR measurements will be analyzed separately when appropriate.
Time frame: Baseline and up to 5 years
Change in Left Ventricular End-Diastolic Dimension
Change in left ventricular end-diastolic dimension (LVEDD), measured in millimeters, from baseline to available follow-up assessments using clinically performed echocardiography. Longitudinal changes will be evaluated using available repeated measurements, with changes from baseline reported.
Time frame: Baseline and up to 5 years
Exploratory Molecular Profiles in Available Biospecimens
Exploratory characterization of molecular profiles in available, appropriately consented blood, body fluid, and tissue specimens. Analyses may include circulating biomarkers, transcriptomic profiles, protein abundance, metabolite profiles, and other approved molecular measurements. Assay-specific quantitative features will be compared across clinical LVHT/LVNC phenotypes. Biospecimen collection and molecular testing are optional and are not required for enrollment.
Time frame: Baseline and up to 5 years, when biospecimens are available
Exploratory Associations Between Molecular Signatures and Clinical Phenotypes
Exploratory assessment of associations between molecular signatures and LVHT/LVNC clinical characteristics, including ventricular function, myocardial fibrosis, trabeculation features, and cardiovascular outcomes. Where suitable tissue specimens are available, analyses may investigate cell-type composition, cell states, molecular pathways, and intercellular signaling. These analyses are exploratory and are not intended to establish causal mechanisms or validate surrogate endpoints.
Time frame: Baseline and up to 5 years
Started Jul 2024 (actual). Primary completion is estimated for Dec 2050, 317 months after the start.
Since we started tracking on Sep 25, 2026, the dates moved once, on Nov 18, 2026: start Oct 2024 → Jul 2024, primary completion Sep 2027 → Dec 2050 and completion Sep 2030 → Dec 2050.
Earlier changes are on the record history on ClinicalTrials.gov ↗
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
First Affiliated Hospital Xi'an Jiaotong University →